Table S1 (Supplementary Table S1). Patient characteristics and outcomes

Characteristic	Overall group *n* = 71 (100%)	Survivors *n* = 17 (23.9%)	Non-survivors *n* = 54 (76.1%)	*p*-value
Age, years	71.7 ± 12	69.7 ± 11	72.1 ± 11	0.8
Gender, males	44 (62%)	14 (82%)	30 (56%)	0.1
LVEF, %	49.8 ± 36	48.1 ± 35.2	64.5 ± 51.6	0.8
Myocardial infarction type				
NSTEMI/STEMI/unknown, (N, (%))	13,(18)/31(44)/27(38)	2(12)/2(12)/13(76)	11(20)/29(54)/14(26)	0.0007
Onset of cardiac arrest				
OHCA/IHCA, (N, (%))	31(44)/24(34)	8(47)/2(12)	23(43)/22(41)	0.1
Initial rhythm at cardiac arrest				
VF/PEA/asystole/unknown, (N, (%))	14(19,7)/33(46,5)/11(15,5)/13(18,3)	1(6)/10(59)/0(0)/6(35)	13(24)/23(43)/11(20)/7(13)	0.1
Patient history				
Hypertension, (N, (%))	30(42)	5(29)	25(46)	0.2
Type 2 Diabetes, (N, (%))	12(17)	2(12)	10(19)	1.0
Previous MI, (N, (%))	13(18)	3(18)	10(19)	1.0
Arrhythmias*, (N, (%))	31(44)	20(12)	11(20)	0.7
Valvular heart disease, (N, (%))	4(6)	1(6)	3(6)	1.0
CKD, (N, (%))	24(34)	20(12)	4(7)	0.6
ICD, N, (%))	4(6)	1(6)	3(6)	1.0
Angiographic findings among patients				
Distribution of diseased vessels				
LM/LAD/Cx/RCA, (N, (%))	21(30)/51(72)/35(49)/36(51)	5(29)/13(76)/9(53)/11(65)	16(30)/38(70)/26(48)/25(46)	-
Infarct-related arteries				
LM/LAD/Cx/RCA, %	17(24)/38(54)/22(31)/19(27)	4(24)/6(35)/6(35)/6(35)	13(24)/32(59)/16(30)/13(24)	-
TIMI grade flow at baseline				
TIMI LM > 1, (N, (%))	5(7)	1(6)	4(7)	1.0
TIMI LAD > 1, (N, (%))	11(15)	4(24)	7(13)	0.2
TIMI Cx> 1, (N, (%))	6(8)	2(12)	4(7)	1.0
TIMI RCA > 1, (N, (%))	9(13)	2(12)	7(13)	1.0
Multi-vessel CAD, (N, (%))	27(38)	6(35,3)	21(39)	1.0
2 vessels, (N, (%))	19(27)	4(23,5)	15(28)	1.0
3 vessels, (N, (%))	8(11)	2(11,8)	6(11)	1.0
Procedural data of patients				
Volume of contrast, mL	180 ± 86	182 ± 62	179 ± 96	0.5
Radiation dose, mGy	898 ± 893	647 ± 404	999 ± 1015	0.2
Respirator, (N, (%))	62 (87)	16 (94)	46 (85)	1.0
Coronarography, (N, (%))	60 (85)	14 (82)	46 (85)	0.2
Radial/femoral/unknown PCI access, (N, (%))	14(20)/51(72)/6(8)	3(18)/12(71)/2(11)	11(20)/39(72)/4(8)	0.8
PCI, (N, (%))	56(79)	11(65)	45(83)	1.0
Balloon angioplasty, (N, (%))	55(77)	14(82)	41(76)	0.3
Stent, (N, (%))	53(75)	14(82)	39(72)	0.2
Thrombectomy, (N, (%))	23(32)	6(35)	17(31)	0.5
Glycoprotein IIb/IIIa inhibitors, (N, (%))	27(38)	6(35)	21(39)	0.7
Endocavitary electrode, (N, (%))	23(32)	2(12)	21(39)	0.4
IABP, (N, (%))	15(21)	6(35)	9(17)	0.2
Pressor amines				
Adrenaline, (N, (%))	31(44)	8(47)	23(43)	0.7
Noradrenaline. (N, (%))	26(37)	7(41)	19(35)	1.0
Dobutamine, (N, (%))	19(27)	4(24)	15(28)	0.5

Dopamine, (N, (%))	12(17)	3(18)	9(17)	1.0

Table S2. Patient characteristics and outcomes

Selected indices	Overall group n = 48 (100%)	OHCA n = 25 (52.1%)	IHCA n = 23 (47.9%)	*p*-value
Age, years	72.6 ± 11.37	71.4 ± 11.57	74 ± 11.27	0.4
Gender, males	27 (56%)	18 (72%)	9 (39%)	**0.04**
LVEF, %	26.8 ± 15.3	27.0 ± 13.9	26.6 ± 16.7	1.0
Myocardial infarction type				
NSTEMI/STEMI/unknown, (N, (%))	12(25)/26(54)/10(21)	5(25)/16(64)/4(16)	7(30)/10(43)/6(27)	0.3
Initial rhythm at cardiac arrest				
VF/PEA/asystole/unknown, (N, (%))	13(27)/22(46)/8(17)/5(10)	6(24)/10(40)/5(20)/4(16)	7(30)/12(52)/3(13)/1(5)	0.5
Patient history				
Hypertension, (N, %))	28(58)	14(56)	14(61)	1.0
Type 2 Diabetes, (N, %))	12(25)	5(20)	7(30)	0.7
Previous MI, (N, %))	10(21)	5(20)	5(22)	1.0
Arrhythmias[a], (N, %))	11(23)	7(28)	4(17)	0.4
Valvular heart disease, (N, (%))	4(8)	3(12)	1(4)	0.6
CKD, (N, (%))	5(10)	2(8)	3(13)	0.7
ICD, (N, (%))	3(6)	1(4)	2(9)	0.6
Angiographic findings among patients				
Distribution of diseased vessels				
LM/LAD/Cx/RCA, (N, (%))	13(27)/36(75)/23(48)/27(56)	6(24)/16(64)/12(48)/13(52)	7(30)/20(87)/11(48)/14(61)	-
Infarct-related arteries				
LM/LAD/Cx/RCA, (N, (%))	10(21)/22(46)/10(21)/14(29)	5(25)/9(36)/5(20)/8(32)	5(22)/13(57)/5(21)/6(26)	-
TIMI grade flow at baseline				
TIMI LM > 1, (N, (%))	29(60)	14(56)	15(65)	0.1
TIMI LAD > 1, (N, (%))	16(33)	10(40)	6(26)	0.3
TIMI Cx> 1, (N, (%))	24(50)	11(44)	13(57)	0.5
TIMI RCA > 1, (N, (%))	19(40)	8(32)	11(48)	0.5
Multivessel CAD, (N, (%))	15(31)	7(28)	8(35)	0.7
2 vessels, (N, (%))	11(23)	6(24)	5(22)	1.0
3 vessels, (N, (%))	4(8)	1(4)	3(13)	0.3
Procedural data of patients				
Procedural data				
Volume of contrast, mL	206.7 ± 27.5	175.7 ± 86.4	250 ± 149.8	0.5
Radiation dose, mGy	1130.8 ± 1150.0	707.5 ± 252.3	1796 ± 1672.2	**0.03**
Respirator, (N, (%))	85	88	83	0.5
Radial/femoral/unknown PCI access, (N, (%))	10(21)/33(69)/5(10)	2(8)/19(76)/4(16)	8(35)/14(61)/1(4)	**0.047**
PCI, (N, (%))	45(94)	23(92)	22(96)	1.0
Balloon angioplasty, (N, (%))	39(81)	19(76)	20(87)	0.1
Stent, (N, (%))	36(75)	19(76)	17(74)	1.0
Thrombectomy, (N, (%)	13(27)	5(20)	8(35)	0.3
GlycoproteinIIb/IIIa inhibitors, (N, (%))	18(38)	9(36)	9(39)	0.8

Endocavitary electrode, (N, (%))	16(33)	5(20)	11(48)	0.1
IABP, (N, (%))	9(19)	5(20)	4(17)	1.0
Pressoramines				
Adrenaline, (N, (%))	21(44)	9(36)	12(52)	0.5
Noradrenaline. (N, (%))	22(46)	12(48)	10(43)	0.3
Dobutamine, (N, (%))	18(38)	9(36)	9(39)	0.7
Dopamine, (N, (%))	13(27)	10(40)	3(13)	**0.01**

*.Data are shown as mean ± standard deviation (SD) or proportions (%). *P*-values below 0.05 were marked in bold.
[a] Arrythmias include: atrial fibrillation, 3rd degree cardiac block and left bundle branch block.
LVEF: left ventricular ejection fraction; NSTEMI: non-ST segment elevation myocardial infarction; STEMI: ST segment elevation myocardial infarction; OHCA: out-of-hospital cardiac arrest; INHCA: in-hospital cardiac arrest; VF: ventricular fibrillation; PEA: pulseless electrical activity; MI: myocardial infarction; CKD: chronic kidney disease; ICD: implantable cardioverter defibrillator; LM: left main coronary artery; LAD: left anterior descending coronary artery; Cx: circumflex coronary artery; RCA: right coronary artery; TIMI: thrombolysis in myocardial ischemia; CAD: coronary artery disease; PCI: percutaneous coronary intervention; IABP: intra-aortic balloon pump.

Table S3. Laboratory data

Selected indices	Overall group $n = 48$ (100%)	OHCA $n = 25$ (52.1%)	IHCA $n = 23$ (47.9%)	*p*-value
aPTT, s	83.9 ± 70.3	85.8 ± 68.3	81.3 ± 75.4	0.7
INR	1.5 ± 1.1	1.6 ± 1.3	1.4 ± 0.7	1.0
Prothrombin time, s	17.3 ± 11.8	18.3 ± 14.5	16.1 ± 7.5	0.9
Hemoglobin, g/dL	12.4 ± 2.3	12.6 ± 2.3	12.1 ± 2.3	0.6
Erythrocytes, x10^6/µL	4.1 ± 0.7	4.0 ± 0.7	4.2 ± 0.6	0.5
Platelets, x10^3/µL	193.7 ± 75.6	168.0 ± 65.5	223.7 ± 77.1	**0.02**
Creatinine, mg/dL	1.8 ± 1.2	1.79 ± 1.1	1.82 ± 1.4	0.4
eGFR, mL/min/1.73 m^2	47.0 ± 23.4	45.5 ± 16.8	48.6 ± 28.9	0.7
Sodium, mmol/L	138.6 ± 4.9	139.2 ± 5.6	138 ± 4.2	0.3
Potassium, mmol/L	4.5 ± 0.9	4.3 ± 0.8	4.7 ± 1.0	0.2

*aPTT: activated partial thromboplastin time; INR: international normalized ratio; eGFR: estimated glomerular filtration rate.

Table S4. Univariate logistic regression analysis of survival predictors with laboratory parameters as dichotomous variables

Predictor	Odds ratio	95% Confidence Interval	*p*-value
Gender, male vs. female	1.65	0.70-3.89	0.3
Prothrombin time >15 s	1.94	0.60-6.28	0.3
Hemoglobin < 10 g/dL	1.53	0.41-5.73	0.5
Platelets < 100x103/µL	2.24	0.57-8.76	0.3
Creatinine > 1.2 mg/dL	1.50	0.51-4.42	0.5
eGFR < 60 mL/min/1.73 m2	1.65	0.56-4.85	0.4
Sodium < 135 mmol/L	0.92	0.19-4.37	0.9
Potassium > 5.0 mmol/L[a]	4.61	1.41-15.05	**0.01**
Glucose > 180 mg/dL	0.55	0.12-2.60	0.5
CRP > 5 mg/dL	1.41	0.38-5.24	0.6
pH < 7.35	1.04	0.30-3.58	1.0
pH < 7.15	0.75	0.28-1.99	0.6
pCO2 > 45 mmHg	1.33	0.50-3.53	0.6

[a]Age- and sex-adjusted ORs and *p*-values.